Harris Williams & Co. Advises Liquent, Inc., a Portfolio Company of Marlin Equity Partners, in its Sale to PAREXEL International Corporation
Harris Williams & Co., a preeminent middle market investment bank focused on the advisory needs of clients worldwide, announces the sale of Liquent, Inc. to PAREXEL International Corporation (NASDAQ:PRXL). Liquent is the leading provider of innovative software and professional services designed to support the regulatory information management processes of global life sciences companies. Liquent was a portfolio company of Marlin Equity Partners (Marlin). Harris Williams & Co. acted as the exclusive financial advisor to Liquent. The transaction closed on December 21, 2012, and was led by Jeffery Bistrong, Sam Hendler, Kojo Appenteng and Dan Linsalata from the firm’s Technology, Telecom & Media (TMT) Group in Boston.
“The rapidly evolving healthcare regulatory environment continues to drive large biopharmaceutical services companies like PAREXEL to acquire specialized software platforms embedded with proprietary knowledge of the approval and compliance process as Liquent’s has. We believe this trend will continue to accelerate through 2013,” said Jeff Bistrong, managing director and co-head of Harris Williams & Co.’s TMT Group.
“Liquent’s proprietary solutions enable its biopharmaceutical and life sciences clients to increase revenue, reduce costs and mitigate compliance risk,” said Sam Hendler, a director in Harris Williams & Co.’s TMT Group who leads the firm’s HCIT practice.
Liquent’s flagship software suite, Liquent InSight®, is the only end-to-end, integrated Regulatory Information Management (RIM) platform available in the market today. The Liquent Direct™ professional services team provides a full complement of flexible Regulatory Affairs consulting and Regulatory Operational outsourcing services designed to meet the demands of a dynamic regulatory landscape. The company is headquartered in Horsham, PA and maintains international offices in Windsor, UK and Bangalore, India.
Marlin is a global private investment firm with over $1 billion of capital under management. The firm is focused on providing corporate parents, shareholders and other stakeholders with tailored solutions that meet their business and liquidity needs. Marlin invests in businesses across multiple industries where its capital base, industry relationships and extensive network of operational resources significantly strengthens a company's outlook and enhances value. Since its inception, Marlin, through its group of funds and related companies, has successfully completed over 60 acquisitions. The firm is headquartered in Los Angeles, CA with an additional office in London.
PAREXEL is a leading global biopharmaceutical services organization, providing a broad range of knowledge-based contract research, consulting and medical communications services to the worldwide pharmaceutical, biotechnology and medical device industries. Committed to providing solutions that expedite time-to-market and peak-market penetration, PAREXEL has developed significant expertise across the development and commercialization continuum, from drug development and regulatory consulting to clinical pharmacology, clinical trials management, medical education and reimbursement.